Chronic Fatigue Syndrome Clinical Trial
Official title:
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
The purpose of this study is to determine how best to manage the sleep problems of people with Chronic Fatigue Syndrome. This study is being conducted to determine how improvements in sleep affect other Chronic Fatigue symptoms including pain, fatigue, and mood as well as a person's sense of general well-being.
Status | Completed |
Enrollment | 24 |
Est. completion date | July 2010 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Chronic Fatigue Syndrome and Insomnia - meet diagnostic criteria for insomnia - be diagnosed with CFS by the Study Physician using CDC criteria - must be in current treatment for CFS (we can provide referrals if needed). - under medical care for a minimum of 6 weeks with a stable medication regimen for > 1 month. Study patients can have comorbid depression (as long as it is not bipolar, melancholic or psychotic) or fibromyalgia. They can be taking sleep medications. Exclusion Criteria: - Those with untreated medical disorders that could account for the fatigue, or affect sleep. Medical conditions that would exclude a participant include: - organ failure resulting from conditions such as emphysema, cirrhosis, cardiac failure, chronic renal failure - chronic infections, including AIDS, and hepatitis B or C - rheumatic and chronic inflammatory diseases that could account for the fatigue: including systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis - major neurologic diseases (e.g., multiple sclerosis, neuromuscular diseases, epilepsy or other diseases requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits) - diseases requiring systemic treatment (e.g., organ or bone marrow transplantation, systemic chemotherapy, radiation of brain, thorax, abdomen, or pelvis) - untreated major endocrine diseases (e.g., hypopituitarism, adrenal insufficiency) - being on medications with known fatigue side effects or medications that have not been stable for at least one month - inadequately-treated hypothyroidism - untreated or unstable diabetes mellitus - active infection - pregnancy, 1-3 months post-partum or breast feeding - within 6 months post-operation for a major surgical procedure - within 3 months post-operation of minor surgery - major infections, such as sepsis or pneumonia until 3 months post-resolution - major conditions whose resolution may be unclear for at least 5 years (e.g., myocardial infarction, heart failure) - terminal conditions - severe obesity as defined as a body mass index (weight in kilograms/height in meters)2 > 40 - elective surgery planned during the trial - We will exclude those who meet DSM-IV criteria currently or in the past 5 years for psychotic or melancholic Major Depression, bipolar disorders, schizophrenia, or eating disorders, alcohol or substance abuse or dependence (e.g., dependence on benzodiazepines or any other substance) - We will exclude those meeting criteria for Narcolepsy, Restless Legs Syndrome, a Circadian Rhythm Disorder, or sleep apnea and/or hypopnea. - We will exclude those with a medication change within the last month to ensure participants are on a stable dose and regimen of medication. *Once potential patients have had a stable medication regimen for > 1 month, participants can enter the trial. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center - Insomnia and Sleep Disorders Lab | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Institute of Nursing Research (NINR) |
United States,
Carney CE, Edinger JD. Identifying critical beliefs about sleep in primary insomnia. Sleep. 2006 Apr;29(4):444-53. — View Citation
Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med. 2005 Nov 28;165(21):2527-35. — View Citation
Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. 2001 Apr 11;285(14):1856-64. — View Citation
Waters WF, Hurry MJ, Binks PG, Carney CE, Lajos LE, Fuller KH, Betz B, Johnson J, Anderson T, Tucci JM. Behavioral and hypnotic treatments for insomnia subtypes. Behav Sleep Med. 2003;1(2):81-101. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | total wake time | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Primary | total sleep time | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Primary | sleep efficiency | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Primary | beliefs about sleep | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Primary | sleep habits | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Secondary | actigraphy (measurement of activity) | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No | |
Secondary | scores on measures of fatigue, mood, anxiety, quality of life, chronic fatigue syndrome symptoms, fibromyalgia symptoms, medication usage | Measures taken at baseline, mid-treatment, immediate post-treatment, one-month follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|
||
Completed |
NCT03844412 -
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
|
Phase 2 |